No quarterly revenue total was found in NEUMORA THERAPEUTICS, INC.'s SEC filings.
Neumora Therapeutics, Inc. (NMRA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $116.8 million in cash and investments and $113.3 million in total debt.
Revenue
—
Net income
$-43.08M
+18.3% vs year-ago quarter
Operating cash flow
$-39.53M
+24.6% vs year-ago quarter
Free cash flow
$-46.65M
EPS
$-0.23
+30.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
187.90M
+16.0% vs year-ago quarter
Net cash
$3.58M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- NMRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Watertown, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1885522
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$42.2M | -$52.9M | -$58.5M | -$57.7M | -$54.0M |
| Net income | -$43.1M | -$53.5M | -$59.5M | -$56.8M | -$52.7M |
| Diluted EPS | -$0.23 | -$0.30 | -$0.35 | -$0.35 | -$0.33 |
| Operating cash flow | -$39.5M | -$46.4M | -$48.0M | -$46.6M | -$52.4M |
| Free cash flow | — | — | — | -$46.6M | — |
| Total assets | $125.2M | $153.9M | $191.0M | $177.8M | $223.8M |
| Total liabilities | $80.7M | $83.2M | $87.2M | $45.7M | $40.9M |
| Stockholders' equity | $44.5M | $70.7M | $103.9M | $132.2M | $182.9M |
| Cash and investments | $116.8M | $147.1M | $182.5M | $171.5M | $217.6M |
| Total debt | $113.3M | $113.4M | $115.0M | $40.1M | $40.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Oct 30, 2026 | Oct 26, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Other events
|
Jul 27, 2026 | Jul 27, 2026 |
| 8-K |
Current report
Material agreement, New debt, Exit or restructuring costs, Regulation FD disclosure, Other events
|
Jun 15, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 29, 2026 | May 27, 2026 |
All 258 Neumora Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.